## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

CLAIMS

We claim:

**1** (Currently amended). ~~Novel anhydrous amorphous forms of bis[(E) [4-(4-fluorophenyl) isopropyl [methyl(methylsulfonyl)amino]pyrimidin yl](3R,5S) 3,5-dihydroxyhept enoic acid]calcium salt (rosuvastatin calcium), bis[(E) 3,5-dihydroxy 7-[4' (4'' fluorophenyl) 2' cyclopropyl quinolin 3' hept 6 enoic acid] calcium salt (pitavastatin calcium) and form of (±)7 (3 (4 fluorophenyl) 1 (1 methylethyl) 1H indol 2-yl) 3,5 dihydroxy heptenoic acid monosodium salt (fluvastatin sodium).~~ Anhydrous amorphous fluvastatin sodium, wherein it is free of water and its X-ray powder diffraction pattern lacking any discernible peaks and substantially in accordance with Figure 3.

**2-7** (Cancelled)

**8** (Currently amended). A process for [[the]] preparation of anhydrous amorphous ~~forms of bis[(E) [4-(4-fluorophenyl) isopropyl [methyl(methylsulfonyl)amino]pyrimidin yl](3R,5S) 3,5-dihydroxyhept enoic acid]calcium salts (rosuvastatin calcium), bis[(E) 3,5-dihydroxy-7-[4'-(4''-fluorophenyl) 2' cyclopropyl quinolin 3' hept 6 enoic acid] calcium salt (pitavastatin calcium) and (±)7 (3 (4 fluorophenyl) 1 (1 methylethyl) 1H indol 2 yl) 3,5 dihydroxy heptenoic acid monosodium salt (fluvastatin sodium)~~ fluvastatin sodium of claim 1, comprising steps of:

(a) Dissolving crude or pure hydrate amorphous or crystalline form or their mixtures of ~~the Agents~~ fluvastatin sodium in a non-hydroxylic solvent;

(b) Adding a non-polar hydrocarbon anti-solvent or adding the dissolved ~~the Agents~~ fluvastatin sodium to the non-polar anti-solvent to precipitate out product;

and (c) removing the solvent by filtration to afford anhydrous amorphous ~~forms of rosuvastatin calcium, pitavastatin calcium and~~ fluvastatin sodium.

**9-12** (Cancelled)

**13** (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is chosen from a group of non-polar hydrocarbon solvents comprising n-hexane, cyclohexane or n-heptane.

**14** (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is n-hexane.

**15** (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is cylcohexane.

**16** (Original). The process according to claim 8, wherein the non-hydroxylic solvent is tetrahydrofuran and anti-solvent is n-heptane.

**17** (Currently amended). The process according to any of claims ~~8-16~~ 8, 11 and 13-16, which comprises cooling the solution and isolating the precipitated anhydrous amorphous form by filtration or centrifuging.

**18** (Currently amended). A process for the preparation of anhydrous amorphous ~~forms of rosuvastatin calcium, pitavastatin calcium and~~ fluvastatin sodium of claim 1 by dissolving crude or pure hydrate amorphous or crystalline forms or their mixtures of ~~the Agents~~ fluvastatin sodium in acetonitrile or in straight or branched alkanol containing 1-4 carbon atoms or a mixture of such alkanols under heating and isolating the anhydrous amorphous ~~form of the Agents~~ fluvastatin sodium precipitated after cooling.

**19-22** (Cancelled)

**23** (Original). The process according to claim 18, alkanol solvent is selected from methanol, ethanol, isopropanol, butanol or their mixtures.

**24** (Original). The process according to claim 18, alkanol solvent is preferably selected from ethanol and isopropanol.

**25** (Original). The process according to claim 18, which comprises using acetonitrile or a mixture of acetonitrile and one or more alkanols.

**26** (Currently amended). The process according to claim 18, which comprises dissolving ~~rosuvastatin calcium or pitavastatin calcium or~~ fluvastatin sodium in alkanols or acetonitrile at the boiling point of the solvent.

**27** (Currently amended). The process according to any of claims ~~18-26~~ 18 and 23-26, which comprises cooling the solution and isolating the precipitated anhydrous amorphous ~~form~~ fluvastatin sodium by filtration or centrifuging.

**28** (Currently amended). A pharmaceutical composition comprising an anhydrous amorphous ~~form of rosuvastatin calcium, piatavstatin calcium or~~ anhydrous amorphous fluvatsatin sodium of claim 1 and pharmaceutically acceptable carrier, diluent, excipient, additive, filler, lubricant, solvent binder or stabilizer.

**29-31** (Cancelled)

**32** (Original). A pharmaceutical composition according to claim 28, in the form of a tablet, troche, powder, syrup, patch, liposome, injection, dispersion, suspension, solutions, capsule, cream, ointment or aerosol.

**33** (Cancelled)